by BioKier | Nov 15, 2025 | Recent News
BioKier has been awarded a $436 K Phase I Small Business Innovation Research (SBIR) Grant by The National Heart, Lung, And Blood Institute (NHLBI), an institute of The National Institutes of Health (NIH). The grant funded submission of an Investigational New Drug...
by BioKier | Jan 26, 2023 | Recent News
Four recent BioKier patent applications were filed and will be published soon. The patents describe the recent clinical discovery that the pharmacological effects of colonic delivery of nutrients can differ depending on the profile of release of the nutrients in the...
by BioKier | Jan 26, 2023 | Recent News
Despite significant delays related to COVID-19, in late 2022 BioKier completed a 12-week clinical study (Study Number CL-501) conducted at three investigational sites: Duke University, Kannapolis NC; Duke University, Pickett Road, NC; and Pennington Biomedical...
by BioKier | Apr 30, 2022 | Recent News
Despite significant delays related to COVID-19, in late 2020 BioKier completed a 4-week study of BKR-017 (orally administered colon-targeted, sustained-release 500 mg butyrate tablets) in type 2 diabetes (T2D) subjects. Dr. Kishore Gadde’s team at Pennington...
by BioKier | Jan 26, 2021 | Recent News
Despite significant delays related to COVID-19, in late 2020 BioKier completed a 4-week study of BKR-017 in type 2 diabetes subjects. Dr. Kishore Gadde’s team at Pennington Biomedical Research Center (PBRC) successfully recruited and enrolled 14 subjects in the study....
